IndraLab
Statements
reach
"Here we described that the adenoviral vector expressing CYLD (Ad/hTERT-CYLD) augmented the cytotoxicity of TRAIL in HCC cells by negatively regulating NF-kappaB activity since CYLD could reverse the ubiquitination of TNF receptor associated factor 2 (TRAF2) and interact with the IkappaB kinasegamma (IKKgamma)."
"We conclude that PrP traps CYLD, preventing it from binding and deubiquitinating RIP1 and TRAF2."
reach
"In support of this notion, in vivo poly-ubiquitination assays demonstrate that depletion of beta-TRCP impaired TRAF6 self ubiquitination likely due to enhancement of TRAF6 deubiquitination by CYLD, concomitant with a reduction in beta-TRCP-dependent ubiquitination of CYLD and impairment of auto-phosphorylation of TRAF6-downstream kinase IKKalpha."
"Other identified CYLD substrates include TNF receptor associated factor 7 (TRAF7), TRAF interacting protein (TRIP), transforming growth factor beta-activated kinase 1 (TAK1), NF-kappa-B essential modifier (NEMO), lymphocyte cell specific protein-tyrosine kinase (LCK), receptor-interacting protein 1 (RIP1), retinoic acid inducible gene (RIG), and polo-like kinase 1 (PLK1)"
"In this region, CYLD associates with its substrate Bcl-3 and prevents the nuclear localization of Bcl3"
reach
"In the present study, the cytoplasmic and perinuclear expression levels of CYLD suggest that CYLD may play a role in the deubiquitination of BCl-3 and/or TRAF in NF-kappaB signaling within the cytoplasm or perinuclear region in keratinocytes of normal skin and cholesteatoma, in agreement with previously reported results."
"Mechanistically, CYLD interacts with and deubiquitinates p53 facilitating its stabilization in response to genotoxic stress.| Collectively, our results identify CYLD as a deubiquitinase facilitating DNA damage-induced p53 activation and suggest that regulation of p53 responses to genotoxic stress contributes to the tumour suppressor function of CYLD."
reach
"Importantly, a phospho-mimetic CYLD mutant harboring serine to glutamic acid substitutions at the phosphorylation sites completely failed to deubiquitinate Tax, whereas a mutant harboring serine to analine mutations at the phsphorylation sites of CYLD (CYLD7SA) remained active in Tax deubiquitination."
CYLD affects IKK_complex
|
4
reach
"Notably, the CYLD USP domain also deubiquitinated STING in vitro (S6D Fig), which is consistent with our observation in S4E Fig. To substantiate this finding, we transfected Flag-STING along with HA-tagged WT ubiquitin or ubiquitin mutants in the presence or absence of CYLD, followed by immunoblotting."
"?To dissect CYLD function we used a proteomics approach to identify CYLD interacting proteins and identified MIB2, an ubiquitin ligase enzyme involved in Notch signalling, as a protein which interacts with CYLD. Coexpression of CYLD and MIB2 resulted in stabilisation of MIB2 protein levels and was associated with reduced levels of JAG2, a ligand implicated in Notch signalling.?"
CYLD affects polyubiquitin chains
|
2
"Other identified CYLD substrates include TNF receptor associated factor 7 (TRAF7), TRAF interacting protein (TRIP), transforming growth factor beta-activated kinase 1 (TAK1), NF-kappa-B essential modifier (NEMO), lymphocyte cell specific protein-tyrosine kinase (LCK), receptor-interacting protein 1 (RIP1), retinoic acid inducible gene (RIG), and polo-like kinase 1 (PLK1)"
reach
"The authors showed that CYLD deubiquitinated RIPK2 in macrophages infected with L. monocytogenes, leading to impaired activation of NF-kappaB, reduced production of proinflammatory cytokines and reactive oxygen and nitrogen species, which ultimately resulted in impaired infection control."
"CYLD-mediated K63 deubiquitination of RIPK2 resulted in an impaired activation of both NF-kappaB and ERK1/2 pathways, reduced production of proinflammatory cytokines interleukin-6 (IL-6), IL-12, anti-listerial reactive oxygen species (ROS) and nitric oxide (NO), and, finally, impaired pathogen control."
"Other identified CYLD substrates include TNF receptor associated factor 7 (TRAF7), TRAF interacting protein (TRIP), transforming growth factor beta-activated kinase 1 (TAK1), NF-kappa-B essential modifier (NEMO), lymphocyte cell specific protein-tyrosine kinase (LCK), receptor-interacting protein 1 (RIP1), retinoic acid inducible gene (RIG), and polo-like kinase 1 (PLK1)"
CYLD affects plakoglobin
|
1
reach
"CYLD : cylindromatosis; DUB : deubiquitylating enzyme; EBNA : Epstein-Barr nuclear antigen; FOXO : forkhead box O; HAUSP : herpesvirus associated ubiquitin specific peptidase; JAMM : Jab1 and MPN domain associated metalloisopeptidase; MJD : Machado-Joseph disease; OUT : ovarian tumor; PD : Parkinson 's disease; RIP : receptor interacting protein; TNF : tumor necrosis factor; TRAF : tumor necrosis factor receptor associated factor; UBP : ubiquitin processing peptidase; USP : ubiquitin specific peptidase; UCH : ubiquitin C-terminal hydrolase; VHL : von Hippel-Lindau."
reach
"CYLD : cylindromatosis; DUB : deubiquitylating enzyme; EBNA : Epstein-Barr nuclear antigen; FOXO : forkhead box O; HAUSP : herpesvirus associated ubiquitin specific peptidase; JAMM : Jab1 and MPN domain associated metalloisopeptidase; MJD : Machado-Joseph disease; OUT : ovarian tumor; PD : Parkinson 's disease; RIP : receptor interacting protein; TNF : tumor necrosis factor; TRAF : tumor necrosis factor receptor associated factor; UBP : ubiquitin processing peptidase; USP : ubiquitin specific peptidase; UCH : ubiquitin C-terminal hydrolase; VHL : von Hippel-Lindau."
"Other identified CYLD substrates include TNF receptor associated factor 7 (TRAF7), TRAF interacting protein (TRIP), transforming growth factor beta-activated kinase 1 (TAK1), NF-kappa-B essential modifier (NEMO), lymphocyte cell specific protein-tyrosine kinase (LCK), receptor-interacting protein 1 (RIP1), retinoic acid inducible gene (RIG), and polo-like kinase 1 (PLK1)"
CYLD affects TNF receptor
|
1
"Other identified CYLD substrates include TNF receptor associated factor 7 (TRAF7), TRAF interacting protein (TRIP), transforming growth factor beta-activated kinase 1 (TAK1), NF-kappa-B essential modifier (NEMO), lymphocyte cell specific protein-tyrosine kinase (LCK), receptor-interacting protein 1 (RIP1), retinoic acid inducible gene (RIG), and polo-like kinase 1 (PLK1)"
"Other identified CYLD substrates include TNF receptor associated factor 7 (TRAF7), TRAF interacting protein (TRIP), transforming growth factor beta-activated kinase 1 (TAK1), NF-kappa-B essential modifier (NEMO), lymphocyte cell specific protein-tyrosine kinase (LCK), receptor-interacting protein 1 (RIP1), retinoic acid inducible gene (RIG), and polo-like kinase 1 (PLK1)"
CYLD affects IKKgamma subunit
|
1
reach
"CYLD : cylindromatosis; DUB : deubiquitylating enzyme; EBNA : Epstein-Barr nuclear antigen; FOXO : forkhead box O; HAUSP : herpesvirus associated ubiquitin specific peptidase; JAMM : Jab1 and MPN domain associated metalloisopeptidase; MJD : Machado-Joseph disease; OUT : ovarian tumor; PD : Parkinson 's disease; RIP : receptor interacting protein; TNF : tumor necrosis factor; TRAF : tumor necrosis factor receptor associated factor; UBP : ubiquitin processing peptidase; USP : ubiquitin specific peptidase; UCH : ubiquitin C-terminal hydrolase; VHL : von Hippel-Lindau."
CYLD affects EBNA
|
1
reach
"CYLD : cylindromatosis; DUB : deubiquitylating enzyme; EBNA : Epstein-Barr nuclear antigen; FOXO : forkhead box O; HAUSP : herpesvirus associated ubiquitin specific peptidase; JAMM : Jab1 and MPN domain associated metalloisopeptidase; MJD : Machado-Joseph disease; OUT : ovarian tumor; PD : Parkinson 's disease; RIP : receptor interacting protein; TNF : tumor necrosis factor; TRAF : tumor necrosis factor receptor associated factor; UBP : ubiquitin processing peptidase; USP : ubiquitin specific peptidase; UCH : ubiquitin C-terminal hydrolase; VHL : von Hippel-Lindau."
CYLD affects E3_Ub_ligase
|
1
CYLD deubiquitinates E3_Ub_ligase. 1 / 1
|
1
CYLD affects Complex I components
|
1